Bahar Özdemir Ulusoy
Bahar Özdemir Ulusoy has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Berkan Armağan
Ankara Bilkent City Hospital, Department of Internal Medicine, Division of Rheumatology
18 shared publications - Serdar Can Güven
Clinic of Rheumatology, Ankara Bilkent City Hospital
17 shared publications - Orhan Küçükşahin
Ankara Yıldırım Beyazıt University
16 shared publications - Ahmet Omma
Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, University of Health Sciences, 06800 Ankara, Turkey
14 shared publications - Abdulsamet Erden
Division of Rheumatology, Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Türkiye
10 shared publications - Esra Kayacan Erdoğan
Ankara Bilkent City Hospital, Department of Internal Medicine, Division of Rheumatology
10 shared publications
Latest Publications
- Open Access
- 7 April 2026
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 21 (5) , 1647-1654
Screening of osteoporosis in patients with ANCA-associated vasculitis (AAV) is quite low: results from a country-wide study
Patients with ANCA-associated vasculitis (AAV) are at increased risk of osteoporosis due to multiple disease- and treatment-related factors. However, real-world data on osteoporosis screening practices in this population remain limited. The aim of this study was to assess osteoporosis screening practices and the prevalence of reduced bone mineral density (BMD) in patients with AAV using a nationwide registry, and to identify factors associated with osteoporosis. This nationwide, retrospective, web-based study was conducted using the Turkish Vasculitis Study Group (TRVaS) database, including patients diagnosed with AAV between January 2000 and December 2023. Patients were evaluated for osteoporosis screening using dual-energy X-ray absorptiometry (DXA) and categorized according to BMD status. Clinical characteristics and potential risk factors were analyzed, and multivariable logistic regression was performed to identify independent predictors of osteoporosis. A total of 528 patients were included (median age 56 years [interquartile range 43–66]; 57.8% male). Of these, 36.2% underwent DXA screening; among screened patients, 40.8% had osteoporosis and 38.7% had osteopenia. In multivariable analysis, older age (odds ratio [OR] 1.03, p = 0.020) and the presence of at least one additional osteoporosis risk factor (OR 2.25, p = 0.049) were independently associated with osteoporosis. This nationwide registry-based study highlights a gap between the recognized risk of osteoporosis in patients with AAV and its implementation in real-world clinical practice. These findings underscore the need for improved screening and comprehensive bone health management strategies in this population.
- 7 April 2026
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 21 (5) , 1647-1654
Open AccessScreening of osteoporosis in patients with ANCA-associated vasculitis (AAV) is quite low: results from a country-wide study
Patients with ANCA-associated vasculitis (AAV) are at increased risk of osteoporosis due to multiple disease- and treatment-related factors. However, real-world data on osteoporosis screening practices in this population remain limited. The aim of this study was to assess osteoporosis screening practices and the prevalence of reduced bone mineral density (BMD) in patients with AAV using a nationwide registry, and to identify factors associated with osteoporosis. This nationwide, retrospective, web-based study was conducted using the Turkish Vasculitis Study Group (TRVaS) database, including patients diagnosed with AAV between January 2000 and December 2023. Patients were evaluated for osteoporosis screening using dual-energy X-ray absorptiometry (DXA) and categorized according to BMD status. Clinical characteristics and potential risk factors were analyzed, and multivariable logistic regression was performed to identify independent predictors of osteoporosis. A total of 528 patients were included (median age 56 years [interquartile range 43–66]; 57.8% male). Of these, 36.2% underwent DXA screening; among screened patients, 40.8% had osteoporosis and 38.7% had osteopenia. In multivariable analysis, older age (odds ratio [OR] 1.03, p = 0.020) and the presence of at least one additional osteoporosis risk factor (OR 2.25, p = 0.049) were independently associated with osteoporosis. This nationwide registry-based study highlights a gap between the recognized risk of osteoporosis in patients with AAV and its implementation in real-world clinical practice. These findings underscore the need for improved screening and comprehensive bone health management strategies in this population.
- 17 February 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (2) , 243-249
Do different organ involvements cause different comorbidity profiles in Behçet’s syndrome?
This study investigated whether different organ involvements in Behçet's syndrome (BS) are associated with distinct comorbidity profiles. A retrospective cohort study was conducted using records of 345 patients who met the 1990 International Study Group criteria for BS. Patients were categorized into three groups based on organ involvement: Vascular (n = 102), Mucocutaneous (n = 94), and 'Others' (n = 149). Data on comorbidities and treatments were collected, and statistical analyses were performed to compare comorbidity frequencies across the groups. Binomial logistic regression was used to examine the relationship between comorbidity profiles and involvement groups. The Mucocutaneous group had the lowest comorbidity rate at 37.2%, while the Vascular group showed the highest rate at 59.8%, with a significant increase in cardiovascular comorbidities such as coronary artery disease and stroke. No significant differences were found in Diabetes Mellitus (DM), hyperlipidemia (HL), or hypertension (HT) between groups. Coronary artery disease and stroke were categorized as 'cardiovascular disease (CVD).' Logistic regression showed that vascular involvement independently predicted CVD, even when adjusted for HT, DM, and HL. Vascular involvement in BS is associated with a higher burden of cardiovascular comorbidities and serves as an independent predictor of CVD. These findings may highlight the need for tailored management strategies based on specific clinical presentations.
- 17 February 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (2) , 243-249
Do different organ involvements cause different comorbidity profiles in Behçet’s syndrome?
This study investigated whether different organ involvements in Behçet's syndrome (BS) are associated with distinct comorbidity profiles. A retrospective cohort study was conducted using records of 345 patients who met the 1990 International Study Group criteria for BS. Patients were categorized into three groups based on organ involvement: Vascular (n = 102), Mucocutaneous (n = 94), and 'Others' (n = 149). Data on comorbidities and treatments were collected, and statistical analyses were performed to compare comorbidity frequencies across the groups. Binomial logistic regression was used to examine the relationship between comorbidity profiles and involvement groups. The Mucocutaneous group had the lowest comorbidity rate at 37.2%, while the Vascular group showed the highest rate at 59.8%, with a significant increase in cardiovascular comorbidities such as coronary artery disease and stroke. No significant differences were found in Diabetes Mellitus (DM), hyperlipidemia (HL), or hypertension (HT) between groups. Coronary artery disease and stroke were categorized as 'cardiovascular disease (CVD).' Logistic regression showed that vascular involvement independently predicted CVD, even when adjusted for HT, DM, and HL. Vascular involvement in BS is associated with a higher burden of cardiovascular comorbidities and serves as an independent predictor of CVD. These findings may highlight the need for tailored management strategies based on specific clinical presentations.
- Open Access
- 1 April 2025
- Published by Joint Diseases and Related Surgery in Joint Diseases and Related Surgery
- Vol. 36 (2) , 366-372
The role of high large unstained cell percentages in ongoing inflammation in the intercritical gout
Joint Diseases and Related Surgery (JDRS), the official journal of the Turkish Joint Diseases Foundation, is an international, peer-reviewed, immediate open access journal. All published articles in JDRS has been free for everyone, without embargo, since 1990.
- 1 April 2025
- Published by Joint Diseases and Related Surgery in Joint Diseases and Related Surgery
- Vol. 36 (2) , 366-372
Open AccessThe role of high large unstained cell percentages in ongoing inflammation in the intercritical gout
Joint Diseases and Related Surgery (JDRS), the official journal of the Turkish Joint Diseases Foundation, is an international, peer-reviewed, immediate open access journal. All published articles in JDRS has been free for everyone, without embargo, since 1990.
- Open Access
- 22 March 2025
- Published by Ministry of Health, Ankara City Hospital in Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
- Vol. 22 (1) , 38-44
Evaluating ChatGPT’s Effectiveness in Providing Medical Information for Pregnant Women with Rheumatic Diseases
Objective: The growing use of ChatGPT as a source of health information highlights the need to assess its accuracy and adequacy. This study evaluated the accuracy and adequacy of ChatGPT (version 3.5) in responding to frequently asked questions from pregnant women with rheumatic diseases in both Turkish and English, aiming to assess its potential as a reliable source of patient information across languages in rheumatology and maternal-fetal medicine. Material and Methods: A total of 36 questions related to pregnancy and rheumatic diseases were obtained from Google and divided into seven subgroups. Questions were posed to ChatGPT in both Turkish and English and responses were evaluated on a 4-point scale by a rheumatologist (Expert 1) and a perinatologist (Expert 2). Mann-Whitney U test was used for statistical analysis (p < 0.05 was considered significant). Results: ChatGPT’s English responses demonstrated a higher rate of accuracy and completeness compared to its Turkish responses. In English, 91.6% of answers were rated as correct, compared to 75.0% in Turkish. Expert 1 rated the average score for Turkish responses as 3.64 ± 0.54 and for English responses as 3.89 ± 0.31, a difference that was statistically significant (p = 0.023). Expert 2 rated Turkish responses with an average score of 3.83 ± 0.37 and English responses with an average score of 3.94 ± 0.23, with no statistically significant difference (p = 0.136). Conclusion: ChatGPT demonstrates promise as an accessible source of information for pregnant women with rheumatic disease, but has limitations in its non-English responses. This highlights the need for improvement in language-specific training of language models. Further research is recommended to explore the performance of ChatGPT across multiple languages and medical specialties.
- 22 March 2025
- Published by Ministry of Health, Ankara City Hospital in Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
- Vol. 22 (1) , 38-44
Open AccessEvaluating ChatGPT’s Effectiveness in Providing Medical Information for Pregnant Women with Rheumatic Diseases
Objective: The growing use of ChatGPT as a source of health information highlights the need to assess its accuracy and adequacy. This study evaluated the accuracy and adequacy of ChatGPT (version 3.5) in responding to frequently asked questions from pregnant women with rheumatic diseases in both Turkish and English, aiming to assess its potential as a reliable source of patient information across languages in rheumatology and maternal-fetal medicine. Material and Methods: A total of 36 questions related to pregnancy and rheumatic diseases were obtained from Google and divided into seven subgroups. Questions were posed to ChatGPT in both Turkish and English and responses were evaluated on a 4-point scale by a rheumatologist (Expert 1) and a perinatologist (Expert 2). Mann-Whitney U test was used for statistical analysis (p < 0.05 was considered significant). Results: ChatGPT’s English responses demonstrated a higher rate of accuracy and completeness compared to its Turkish responses. In English, 91.6% of answers were rated as correct, compared to 75.0% in Turkish. Expert 1 rated the average score for Turkish responses as 3.64 ± 0.54 and for English responses as 3.89 ± 0.31, a difference that was statistically significant (p = 0.023). Expert 2 rated Turkish responses with an average score of 3.83 ± 0.37 and English responses with an average score of 3.94 ± 0.23, with no statistically significant difference (p = 0.136). Conclusion: ChatGPT demonstrates promise as an accessible source of information for pregnant women with rheumatic disease, but has limitations in its non-English responses. This highlights the need for improvement in language-specific training of language models. Further research is recommended to explore the performance of ChatGPT across multiple languages and medical specialties.
- 2 March 2025
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 19 (5) , 149-156
Novel inflammatory biomarkers for discriminating vascular involvement in Behçet’s syndrome: evaluating SII, SIRI, and NPAR
This study aims to investigate discriminatory ability of the Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), and Neutrophil Percentage-to-Albumin Ratio (NPAR), in differentiating Behçet's Syndrome (BS) organ involvements from mucocutaneous involvement. This retrospective cohort study analyzed 436 patients diagnosed with BS from 2018 to 2023. Patients were categorized into three groups based on organ involvement: vascular, only mucocutaneous, and other organ involvement. Receiver Operating Characteristic (ROC) analysis was used to evaluate the discriminatory ability (mucocutaneous vs rest, vascular vs rest). DeLong's test was used to determine statistical differences in discriminatory power between the models. Out of 436, 115 patients had vascular involvement. SII, SIRI, and NPAR were notably elevated in the vascular involvement group (p < 0.001). ROC analysis revealed that, SII, SIRI and NPAR showed discriminative ability for vascular involvement with AUCs of 0.87 for SII, 0.87 for SIRI, and 0.88 for NPAR. Pairwise comparisons using DeLong's test indicated that all three models performed similarly. SII, SIRI, and NPAR are promising noninvasive biomarkers for predicting vascular involvement. These indices, derived from routine laboratory tests, could enhance early screening and may improve patient outcomes by enabling timely intervention.
- 2 March 2025
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 19 (5) , 149-156
Novel inflammatory biomarkers for discriminating vascular involvement in Behçet’s syndrome: evaluating SII, SIRI, and NPAR
This study aims to investigate discriminatory ability of the Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), and Neutrophil Percentage-to-Albumin Ratio (NPAR), in differentiating Behçet's Syndrome (BS) organ involvements from mucocutaneous involvement. This retrospective cohort study analyzed 436 patients diagnosed with BS from 2018 to 2023. Patients were categorized into three groups based on organ involvement: vascular, only mucocutaneous, and other organ involvement. Receiver Operating Characteristic (ROC) analysis was used to evaluate the discriminatory ability (mucocutaneous vs rest, vascular vs rest). DeLong's test was used to determine statistical differences in discriminatory power between the models. Out of 436, 115 patients had vascular involvement. SII, SIRI, and NPAR were notably elevated in the vascular involvement group (p < 0.001). ROC analysis revealed that, SII, SIRI and NPAR showed discriminative ability for vascular involvement with AUCs of 0.87 for SII, 0.87 for SIRI, and 0.88 for NPAR. Pairwise comparisons using DeLong's test indicated that all three models performed similarly. SII, SIRI, and NPAR are promising noninvasive biomarkers for predicting vascular involvement. These indices, derived from routine laboratory tests, could enhance early screening and may improve patient outcomes by enabling timely intervention.
- Open Access
- 25 February 2025
- Published by Hitit University in Hitit Medical Journal
- Vol. 7 (1) , 53-60
Comorbidity Profile of Familial Mediterranean Fever Patients Varies by Treatments
Objective: Comorbidities may have an impact on the patient’s quality of life and even survival. Treatment resistance in Familial Mediterranean Fever (FMF) may indirectly indicate severe disease, with inflammation-related comorbidities increasing as severity rises. In the literature, there are no sufficient studies regarding comorbidities in FMF patients. In this study, we aimed to evaluate the comorbid conditions of patients according to FMF treatment steps. Material and Method: We retrospectively reviewed 740 patients with FMF treated at our rheumatology clinic between May 2019 and March 2024. Patient characteristics, comorbidities, and FMF treatments of patients were evaluated. Patients were grouped according to their FMF treatment: coated colchicine, compressed colchicine, and IL-1 inhibition. Patients received treatments aligned with their disease activity, in accordance with current reimbursement guidelines. Results: The mean age (SD) of FMF patients was 40.7 (13.3) and 62.4% were female. Of the 44.7% all patients had at least one comorbidity. The three most common comorbidities are hypertension (20%), hyperlipidemia (7%), and depression (6.8%). The initial coated colchicine treatment was changed in a total of 24.5% to compressed colchicine, further step up was done in 13.2% patients to IL-1 inhibition. Hypertension and chronic kidney disease were more common in patients under IL-1 inhibitor treatment. Conclusion: Our retrospective analysis shows that FMF patients, especially those in the IL-1 inhibitor group, frequently experience comorbidities like hypertension, hyperlipidemia, and depression, even though these patients are younger, suggesting a potential link to severe disease. A comprehensive evaluation of comorbidities, especially in severe disease, is essential to prevent complications, and improve quality of life.
- 25 February 2025
- Published by Hitit University in Hitit Medical Journal
- Vol. 7 (1) , 53-60
Open AccessComorbidity Profile of Familial Mediterranean Fever Patients Varies by Treatments
Objective: Comorbidities may have an impact on the patient’s quality of life and even survival. Treatment resistance in Familial Mediterranean Fever (FMF) may indirectly indicate severe disease, with inflammation-related comorbidities increasing as severity rises. In the literature, there are no sufficient studies regarding comorbidities in FMF patients. In this study, we aimed to evaluate the comorbid conditions of patients according to FMF treatment steps. Material and Method: We retrospectively reviewed 740 patients with FMF treated at our rheumatology clinic between May 2019 and March 2024. Patient characteristics, comorbidities, and FMF treatments of patients were evaluated. Patients were grouped according to their FMF treatment: coated colchicine, compressed colchicine, and IL-1 inhibition. Patients received treatments aligned with their disease activity, in accordance with current reimbursement guidelines. Results: The mean age (SD) of FMF patients was 40.7 (13.3) and 62.4% were female. Of the 44.7% all patients had at least one comorbidity. The three most common comorbidities are hypertension (20%), hyperlipidemia (7%), and depression (6.8%). The initial coated colchicine treatment was changed in a total of 24.5% to compressed colchicine, further step up was done in 13.2% patients to IL-1 inhibition. Hypertension and chronic kidney disease were more common in patients under IL-1 inhibitor treatment. Conclusion: Our retrospective analysis shows that FMF patients, especially those in the IL-1 inhibitor group, frequently experience comorbidities like hypertension, hyperlipidemia, and depression, even though these patients are younger, suggesting a potential link to severe disease. A comprehensive evaluation of comorbidities, especially in severe disease, is essential to prevent complications, and improve quality of life.
- Open Access
- 15 January 2025
- Published by LookUs Bilisim A.S. in Medical Records
- Vol. 7 (1) , 167-172
The Role of Prognostic Nutritional Index in Vascular Behçet’s Syndrome
Aim: This study aimed to evaluate the levels of the Prognostic Nutritional Index (PNI) in vascular and non-vascular subtypes of Behçet’s Syndrome (BS) and its potential utility in distinguishing vascular involvement. Material and Method: This retrospective cohort study included 386 patients diagnosed with BS based on ISG criteria. Patients were categorized into vascular (n=100) and non-vascular (n=286) involvement groups. Subgroup analyses assessed organ-specific patterns of involvement. PNI values were calculated as 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (/mm3). Statistical analyses were performed to compare PNI levels between subgroups. Additionally, ROC curve analysis was conducted to evaluate the discriminatory ability of PNI for detecting vascular involvement. Results: Patients with vascular involvement exhibited significantly lower mean PNI values (51.7±6.6) compared to the non-vascular group (56.9±4.4, p
- 15 January 2025
- Published by LookUs Bilisim A.S. in Medical Records
- Vol. 7 (1) , 167-172
Open AccessThe Role of Prognostic Nutritional Index in Vascular Behçet’s Syndrome
Aim: This study aimed to evaluate the levels of the Prognostic Nutritional Index (PNI) in vascular and non-vascular subtypes of Behçet’s Syndrome (BS) and its potential utility in distinguishing vascular involvement. Material and Method: This retrospective cohort study included 386 patients diagnosed with BS based on ISG criteria. Patients were categorized into vascular (n=100) and non-vascular (n=286) involvement groups. Subgroup analyses assessed organ-specific patterns of involvement. PNI values were calculated as 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (/mm3). Statistical analyses were performed to compare PNI levels between subgroups. Additionally, ROC curve analysis was conducted to evaluate the discriminatory ability of PNI for detecting vascular involvement. Results: Patients with vascular involvement exhibited significantly lower mean PNI values (51.7±6.6) compared to the non-vascular group (56.9±4.4, p
- Open Access
- 24 September 2024
- Published by LookUs Bilisim A.S. in Medical Records
- Vol. 6 (3) , 324-328
Age-Related Variations in Treatment Patterns for Axial Spondyloarthritis
Aim: This study examines treatment patterns and preferences among patients diagnosed with Axial Spondyloarthritis (AxSpA) across different age groups. Material and Method: Ankara Bilkent City Hospital registry enabled a comprehensive cross-sectional analysis of 2,811 patients stratified into three age groups: 18-40, 41-55, and over 55 years. These groups were compared in terms of their treatments. Results: Our findings indicate an increasing prevalence of female patients and comorbidities with age. Medication usage patterns showed a trend towards increased use of Methotrexate and Colchicine with age, while Sulfasalazine and Leflunomide were more commonly prescribed in older age groups. Notably, the use of biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs), including anti-Tumor Necrosis Factor (anti-TNF)", "anti-Interleukin (anti-IL) agents, demonstrated a declining trend with advancing age, though not reaching statistical significance. This trend was also reflected in gender-specific treatment distributions, where no significant difference was found in bDMARDs administration among patients over 55 years, contrasting with a higher usage rate in younger male patients. Conclusion: Our study highlights a shift towards more conservative treatment approaches, such as increased conventional synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) use in older patients, likely due to their safety profile and the specific challenges associated with treating older adults, including higher comorbidity rates and medication side effects. These findings emphasize the need for personalized treatment strategies and suggest potential adjustments in clinical practices to better accommodate the aging population, advocating for ongoing research to optimize treatment efficacy and safety for elderly patients with AxSpA.
- 24 September 2024
- Published by LookUs Bilisim A.S. in Medical Records
- Vol. 6 (3) , 324-328
Open AccessAge-Related Variations in Treatment Patterns for Axial Spondyloarthritis
Aim: This study examines treatment patterns and preferences among patients diagnosed with Axial Spondyloarthritis (AxSpA) across different age groups. Material and Method: Ankara Bilkent City Hospital registry enabled a comprehensive cross-sectional analysis of 2,811 patients stratified into three age groups: 18-40, 41-55, and over 55 years. These groups were compared in terms of their treatments. Results: Our findings indicate an increasing prevalence of female patients and comorbidities with age. Medication usage patterns showed a trend towards increased use of Methotrexate and Colchicine with age, while Sulfasalazine and Leflunomide were more commonly prescribed in older age groups. Notably, the use of biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs), including anti-Tumor Necrosis Factor (anti-TNF)", "anti-Interleukin (anti-IL) agents, demonstrated a declining trend with advancing age, though not reaching statistical significance. This trend was also reflected in gender-specific treatment distributions, where no significant difference was found in bDMARDs administration among patients over 55 years, contrasting with a higher usage rate in younger male patients. Conclusion: Our study highlights a shift towards more conservative treatment approaches, such as increased conventional synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) use in older patients, likely due to their safety profile and the specific challenges associated with treating older adults, including higher comorbidity rates and medication side effects. These findings emphasize the need for personalized treatment strategies and suggest potential adjustments in clinical practices to better accommodate the aging population, advocating for ongoing research to optimize treatment efficacy and safety for elderly patients with AxSpA.
- 11 September 2024
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 137 (1-2) , 49-55
Obesity might not alter tofacitinib drug survival in rheumatoid arthritis patients
Summary Introduction Obese rheumatoid arthritis (RA) patients often show reduced responses to traditional treatments, including TNF inhibitors (TNFi). Considering the different mechanisms of action it is important to evaluate the efficacy of tofacitinib in obese patients. This study aims to explore the impact of obesity on the drug survival of tofacitinib in RA patients. Material and methods This retrospective cohort study included RA patients treated with tofacitinib. Patients were categorized into obese (BMI ≥ 30 kg/m2) and non-obese (BMI < 30 kg/m2) groups. The primary outcome was drug survival, assessed using Kaplan-Meier and logistic regression analyses. Results The study comprised 80 RA patients, with 31 (39%) classified as obese. At the 12-month mark, the drug survival rate for tofacitinib was higher in the obese group (81%) compared to the non-obese group (59%). Contrary to univariable analysis, multivariate analysis did not identify obesity as a significant predictor of drug survival. Other variables including sex, hypertension, diabetes mellitus, and anti–cyclic citrullinated peptide (anti-CCP) positivity also showed no significant association with tofacitinib drug survival. Conclusion The findings indicate that obesity does not alter the drug survival rate for tofacitinib among RA patients. Univariate analysis reported a potentially higher drug survival rate in obese patients; however, the lack of statistical significance in multivariate analysis and the study’s retrospective nature necessitate further research to validate these observations and guide personalized therapeutic strategies for this population.
- 11 September 2024
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 137 (1-2) , 49-55
Obesity might not alter tofacitinib drug survival in rheumatoid arthritis patients
Summary Introduction Obese rheumatoid arthritis (RA) patients often show reduced responses to traditional treatments, including TNF inhibitors (TNFi). Considering the different mechanisms of action it is important to evaluate the efficacy of tofacitinib in obese patients. This study aims to explore the impact of obesity on the drug survival of tofacitinib in RA patients. Material and methods This retrospective cohort study included RA patients treated with tofacitinib. Patients were categorized into obese (BMI ≥ 30 kg/m2) and non-obese (BMI < 30 kg/m2) groups. The primary outcome was drug survival, assessed using Kaplan-Meier and logistic regression analyses. Results The study comprised 80 RA patients, with 31 (39%) classified as obese. At the 12-month mark, the drug survival rate for tofacitinib was higher in the obese group (81%) compared to the non-obese group (59%). Contrary to univariable analysis, multivariate analysis did not identify obesity as a significant predictor of drug survival. Other variables including sex, hypertension, diabetes mellitus, and anti–cyclic citrullinated peptide (anti-CCP) positivity also showed no significant association with tofacitinib drug survival. Conclusion The findings indicate that obesity does not alter the drug survival rate for tofacitinib among RA patients. Univariate analysis reported a potentially higher drug survival rate in obese patients; however, the lack of statistical significance in multivariate analysis and the study’s retrospective nature necessitate further research to validate these observations and guide personalized therapeutic strategies for this population.
- 29 May 2024
- Published by Acibadem Universitesi Saglik Bilimleri Dergisi in Acibadem Universitesi Saglik Bilimleri Dergisi
Impact of the long-term hydroxychloroquine use on COVID-19 severity in patients with autoimmune rheumatic disease
Background-Aim: After the numerous studies, the clinical effectiveness of hydroxychloroquine (HCQ) against SARS-CoV-2 is now accepted limited. Besides this, HCQ has still been the first option in most rheumatology practices. To evaluate the frequency, severity and complication of COVID-19 in patients with autoimmune rheumatologic disease (ARD) receiving and not receiving long-term HCQ. Methods: A total of 309 ARD patients were retrospectively evaluated for COVID-19 disease with a SARS-CoV-2 RT-PCR and IgM/IgG antibody.Patients were grouped as HCQ or non-HCQ groups. COVID-19 clinical symptoms development of viral pneumonia, rates of hospitalization, mortality due to COVID-19 and time from initial symptom to viral pneumonia, clinical recovery and RT-PCR negativity were evaluated. Results: During the 13 month study period, 54 (17.4%) were diagnosed with COVID-19, the frequency of COVID-19 was similar between the HCQ (17.9%) and non-HCQ groups (16.7%), p=0.793. The frequency of the myalgia, arthralgia and sore throat were higher in the non-HCQ group, the frequency of other clinical signs and symptoms were higher in the HCQ group but none of them reached statistical significance. In all patients, viral pneumonia was diagnosed in 9 (16.7%), requiring hospitalization in 8 (14.8%), requiring oxygen therapy in 4 (7.4 %) patients and these severe COVID-19 clinical features were similar between groups. COVID-19 complications were seen in 2 patients, 1 of whom was mortality due to ARDS and one was supraventricular tachycardia but thromboembolism or rheumatologic disease activation were not observed. Conclusions: As with the frequency of COVID-19, severity of COVID19 were similar between patients with and without long-term HCQ use in ARD. COVID 19 complications were found to be rare in our study.
- 29 May 2024
- Published by Acibadem Universitesi Saglik Bilimleri Dergisi in Acibadem Universitesi Saglik Bilimleri Dergisi
Impact of the long-term hydroxychloroquine use on COVID-19 severity in patients with autoimmune rheumatic disease
Background-Aim: After the numerous studies, the clinical effectiveness of hydroxychloroquine (HCQ) against SARS-CoV-2 is now accepted limited. Besides this, HCQ has still been the first option in most rheumatology practices. To evaluate the frequency, severity and complication of COVID-19 in patients with autoimmune rheumatologic disease (ARD) receiving and not receiving long-term HCQ. Methods: A total of 309 ARD patients were retrospectively evaluated for COVID-19 disease with a SARS-CoV-2 RT-PCR and IgM/IgG antibody.Patients were grouped as HCQ or non-HCQ groups. COVID-19 clinical symptoms development of viral pneumonia, rates of hospitalization, mortality due to COVID-19 and time from initial symptom to viral pneumonia, clinical recovery and RT-PCR negativity were evaluated. Results: During the 13 month study period, 54 (17.4%) were diagnosed with COVID-19, the frequency of COVID-19 was similar between the HCQ (17.9%) and non-HCQ groups (16.7%), p=0.793. The frequency of the myalgia, arthralgia and sore throat were higher in the non-HCQ group, the frequency of other clinical signs and symptoms were higher in the HCQ group but none of them reached statistical significance. In all patients, viral pneumonia was diagnosed in 9 (16.7%), requiring hospitalization in 8 (14.8%), requiring oxygen therapy in 4 (7.4 %) patients and these severe COVID-19 clinical features were similar between groups. COVID-19 complications were seen in 2 patients, 1 of whom was mortality due to ARDS and one was supraventricular tachycardia but thromboembolism or rheumatologic disease activation were not observed. Conclusions: As with the frequency of COVID-19, severity of COVID19 were similar between patients with and without long-term HCQ use in ARD. COVID 19 complications were found to be rare in our study.